MAIN RESULTS OF CLINICAL RESEARCH IN ONCOLOGY IN FIRST HALF OF THE YEAR 2010


Cite item

Full Text

Abstract

Currently, monoclonal antibodies play an important role in the treatment of solid tumors. Usually they are used in combination with chemotherapy or radiotherapy, because in themselves have limited antitumor activity. Specificity of monoclonal antibodies with combining into conjugates with cytotoxic drugs, toxins or radionuclides, allows to achieve targeted delivery to tumor cells. Although previously immunoconjugates do not find application in the clinical practice, improvement of technology of their manufacture and use of more potent cytotoxic agents led to the development of immunoconjugates with advanced properties. It is very likely that in the near term, immunoconjugates could play an important role in the treatment of patients with solid malignant tumors.

References

  1. Mei Hwei Chang.Prevention of hepatocellular carcinoma through universal vaccination against hepatitis B. ASCO Educational book. Chicago 2010:26-29.
  2. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003;100:776-81.
  3. Helleday T, Peterman E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
  4. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000;408:433-39.
  5. Ford JM. Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. Mutat Res 2005;577:195-202.
  6. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-23.
  7. Banasik M, Komura H, Shimoyama M, et al. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 1992;267:1569-75.
  8. Kummar S, Hinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly(ADP-ribose) polymerase inhibitor ABT-888 in parents with advanced malignancies. J Clin Oncol 2009;27:2705-11.
  9. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gem-citabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009;27:18s(Suppl):abstr.
  10. Fong PC, Boss DS, Yap ÒÀ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
  11. Hiramoto T, Nakanishi T, Sumiyoshi T, et al. Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. Oncogene 1999;18:3422-26.
  12. Schoenmakers EF, Huysmans C, Van de Ven WJ. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res 1999;59:19-23.
  13. Mohaghegh P, Hickson ID. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. Hum Mol Genet. 2001;10:741-46.
  14. Matsuura S, Tauchi H, Nakamura A, et al. Positional cloning of the gene for Nijmegen breakage syndrome. Nat Genet 1998;19:179-81.
  15. Alii E, Sharma VB, Sunderesakumar P, et al. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009;69:3589-96.
  16. Hudis NA. Trastuzumab - mechanisms of action and use in clinical practice. N Engl J Med 2007;357:39-51.
  17. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349-56.
  18. Larson RA, Sievers EL, Stadtmauer EA, et al. Pinal report of the efficacy and safety of gemtuzumab oxogamicin (Mylotarg) in patients with CD33- positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-52.
  19. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-46.
  20. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER-2-positive breast cancer with trastuzumab-DMl, and antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-290.
  21. Pollack VA, Alvarez E, Tse KF, et al. Treatment parameters modulating regression of human melanoma xerograms by an antibody-drug conjugate (CROll-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007;60:423-35.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies